Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Core Insights - Arcutis Biotherapeutics, Inc. will present two posters at the 2025 American Academy of Dermatology annual meeting, focusing on the safety and efficacy of roflumilast cream and foam in treating atopic dermatitis and psoriasis [1][2][3] Group 1: Clinical Trials and Data - The company will present data from two Phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2) that demonstrate the pooled safety and local tolerability of roflumilast cream 0.15% in adults and children with atopic dermatitis who had prior inadequate responses to topical treatments [2][5] - A second presentation will highlight significant improvements in patient-related outcomes with roflumilast foam 0.3% in individuals older than 12 years with psoriasis of the scalp and body [2][7] Group 2: Product Information - Roflumilast cream 0.3% is FDA-approved for the topical treatment of plaque psoriasis in patients aged 6 years and older, while roflumilast cream 0.15% is approved for mild to moderate atopic dermatitis in the same age group [6][9] - ZORYVE foam 0.3% is under FDA review for the treatment of scalp and body psoriasis, with a target action date of May 22, 2025 [8] Group 3: Educational Initiatives - Arcutis will support educational sessions on Culturally Conscious Dermatology™ at the conference, providing attendees with insights into culturally sensitive dermatological care [4]